Both those receiving either expected or less-than-expected starting dosages of ruxolitinib for myelofibrosis treatment ...

For combination therapy, the FDA recommends 200 mg of penpulimab-kcqx every 3 weeks. Monotherapy is recommended at 200 mg ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

The findings, which were presented at the 50th Annual Oncology Nursing Society Congress, showed that at a median follow-up of ...

Panelists discuss how advanced practice providers (APPs) implement effective monitoring strategies for patients with chronic myeloid leukemia (CML), including regular check-ins after starting new ...

When treating patients with hormone-receptor positive, HER2-negative metastatic breast cancer, mutations necessitate the ...

Emetogenic chemotherapy regimens and back pain were associated with higher symptom burden in older, vs younger, patients with ...

Educating patients on the “risks and benefits” of clinical trials is a part of the pipeline for better treatment options in myeloproliferative neoplasms (MPNs) in which nurses can engage, said a nurse ...

Providing education about patients’ diseases was difficult, according to 32% of registered nurses and 29% of infusion nurses.

Apalutamide decreased risk of death in mCSPC by 23% and 26% compared with enzalutamide and abiraterone acetate, respectively.

Oncology nurses can support patients facing financial toxicity by offering guidance on available resources and providing ...

The MindCap mobile app is likely feasible as an assessment for cognitive function of cancer survivors, although further data ...